March 9, 2009
Genavia Therapeutics Licenses Technology from Origen Therapeutics for Cost-Efficient Production of Human Therapeutics in Chicken Eggs.

March 6, 2009
Symphogen and Origen Collaborate to Produce Transgenic Chicken for generation of Fully Human Antibody Therapeutics.

June 23, 2008
Genavia Therapeutics Licenses Technology from Origen Therapeutics for Cost-Efficient Production of Human Therapeutics in Chicken Eggs.

October 3, 2007
Origen Therapeutics Receives $2 Million ATP Grant to Advance Technology for Discovery and Production of Human Polyclonal Antibodies from Transgenic Chickens.

June 7, 2006
Origen Therapeutics Publishes in Nature a Robust and Versatile Method for Creating Transgenic Chickens.

August 29, 2005
First Production of Human Monoclonal Antibodies in Chicken Eggs Published in Nature Biotechnology.

February 18, 2004
Origen Therapeutics Receives SBIR Grant Aimed at Furthering Human Polyclonal Antibody Development in Chickens.